Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Ensysce Biosciences Inc (ENSC)

Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product ACCESSWIRE - Tue Dec 10, 2:00AM CST

~ Supply Chain Now Fully Secure for PF614-MPAR ~

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR ACCESSWIRE - Wed Dec 4, 2:00AM CST

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split ACCESSWIRE - Tue Dec 3, 10:15AM CST

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial ACCESSWIRE - Tue Nov 26, 2:00AM CST

~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~

ENSC : 8.10 (+1.89%)
Wall Street - shutterstock_1321462400
Stocks Set to Open Mixed as Investors Await FOMC Minutes, U.S. Payrolls Data Barchart - Mon Jul 3, 2023

September S&P 500 futures (ESU23) are down -0.08%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.01% this morning at the start of a holiday-shortened week, with market participants looking...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
AAPL : 254.49 (+1.88%)
NVDA : 134.70 (+3.08%)
MCHP : 55.51 (-0.86%)
ON : 65.50 (+1.08%)
CCL : 26.80 (+6.43%)
NKE : 76.94 (-0.21%)
G.M.DX : 26.990 (-0.18%)
TSLA : 421.06 (-3.46%)
NIO : 4.54 (+3.18%)
LI : 23.56 (+0.90%)
Ensysce Biosciences (NASDAQ: ENSC) Successfully Completes Overdose-Protection Study Spotlight Growth - Tue May 9, 2023

Ensysce Biosciences, Inc. (NASDAQ: ENSC) operates as a clinical-stage biotechnology company, which is focused on leveraging its proprietary technology to

ENSC : 8.10 (+1.89%)
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call AccessWire - Wed Jul 27, 2022

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences,...

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)
Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study AccessWire - Wed Jul 13, 2022

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)
Ensysce Biosciences Secures $8 Million Convertible Note Financing AccessWire - Fri Jul 1, 2022

~ Additional Funding from Investor Cohort Validates Company's Mission ~

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform AccessWire - Mon Jun 27, 2022

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...

ENSC : 8.10 (+1.89%)
ENSCW : 0.0180 (-9.55%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here Barchart - Sun Dec 22, 9:30AM CST
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot